“Meta-guidelines” for the management of patients with schizophrenia

Stahl, Stephen M.; Morrissette, Debbi Ann; Citrome, Leslie; Saklad, Stephen R.; Cummings, Michael; Meyer, Jonathan M.; O’Day, Jennifer; Dardashti, Laura J.; Warburton, Katherine

doi:10.1017/s109285291300014x

Cited by 58 publications

(44 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 Another option will be in the future the development of metaguidelines. The term has been recently used to describe the undertaking of collecting recommendations from various sources, then updating and reconciling the differences, in the context of the management of patients with schizophrenia, 19 but can easily be transposed in the field of oncology.…”

Section: Discussionmentioning

confidence: 99%

Adherence to Guidelines in Gynecologic Cancer Surgery

Ferron¹,

Martinez²,

Gladieff³

et al. 2014

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

The purpose of this study is to review the available evidence documenting the prognostic role of adherence to guidelines in gynecologic cancers. A systematic review of the PubMed database using "guideline," "adherence," and "cancer" was carried out on February 25, 2014. Two thousand one hundred twenty-three publications were identified. Only publications addressing the question of adherence to recommendations regarding surgical care and multidisciplinary management of gynecologic cancers were selected. Six studies were identified in endometrial cancer, 4 in ovarian cancer, and none in cervical cancer. Adoption of guidelines is an effective tool for disease control and must consequently be considered as a process measure of quality cancer care. It is urgent to develop reliable and reproducible tools to assess adherence to guidelines based on level 1 evidence in gynecologic cancer then to carry out investigations to document the prognostic impact of compliance with guidelines. The time has come to include adherence to guidelines in quality assurance programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to Guidelines in Gynecologic Cancer Surgery

Ferron¹,

Martinez²,

Gladieff³

et al. 2014

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Psychiatrists reported prescribing SGAs (oral and LAI) for most of their schizophrenic patients, as recommended as first-line treatment by international guidelines for the management of schizophrenia [15]. The prescription rate of LAI formulation appeared higher in comparison with other recent French studies (10%–15%) [16,17].…”

Section: Discussionmentioning

confidence: 99%

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics

Samalin

Garnier

Auclair³

et al. 2016

IJMS

View full text Add to dashboard Cite

The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during six regional French conferences (Bordeaux, Lyon, Marseille, Nice, Paris, and Strasbourg). Data on the characteristics of practice, prescription rates of antipsychotic, and information sources about their clinical decisions were collected. Most psychiatrists used second-generation antipsychotics (SGAs), and preferentially an oral formulation, in the treatment of schizophrenia. LAI SGAs were prescribed to 30.4% of schizophrenic patients. The duration and type of practice did not influence the class or formulation of antipsychotics used. The clinicians following the higher percentage of schizophrenic patients were associated with a higher use of LAI antipsychotics and a lower use of oral SGAs. Personal experience, government regulatory approval, and guidelines for the treatment of schizophrenia were the three main contributing factors guiding clinicians’ decision-making regarding the treatment of schizophrenia. The more clinicians follow schizophrenic patients, the more they use LAI antipsychotics. The development of specialized programs with top specialists should lead to better use of LAI antipsychotics in the treatment of schizophrenia.

show abstract

“…US (Patient Outcomes Research Team) guidelines similarly suggest that LAIs should be offered for patients who would prefer a long-acting formulation over oral medication [55]. Meta-guidelines (derived from both published and unpublished sources) suggest that LAIs should be considered if treatment nonadherence is suspected as contributing towards relapse risk, or for patients with persistent suicidal or hostile behaviour [56]. There remains insufficient evidence for guidelines to recommend a specific LAI over another [19,55,56].…”

Section: Current Status Of Aripiprazole (Abilify Maintena ò ) In the mentioning

confidence: 99%

“…Meta-guidelines (derived from both published and unpublished sources) suggest that LAIs should be considered if treatment nonadherence is suspected as contributing towards relapse risk, or for patients with persistent suicidal or hostile behaviour [56]. There remains insufficient evidence for guidelines to recommend a specific LAI over another [19,55,56]. The choice of agent should be made by the patient and healthcare professional together, and should be based on the individual patient's situation with an evaluation of the risk-benefit profile, with particular consideration given to potential adverse events including metabolic changes and EPS [19].…”

Section: Current Status Of Aripiprazole (Abilify Maintena ò ) In the mentioning

confidence: 99%

Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia

Shirley¹,

Perry²

2014

Drugs

View full text Add to dashboard Cite

Aripiprazole (ABILIFY(®)) is an atypical antipsychotic drug that is proposed to act via partial agonism of dopamine D2 receptors. Trials with oral aripiprazole have shown that, compared with some other atypical antipsychotics, aripiprazole is associated with fewer metabolic disturbances and has a favourable cardiovascular tolerability profile. Recently, an intramuscular long-acting injectable (LAI) depot formulation of aripiprazole (ABILIFY MAINTENA(®)) (aripiprazole LAI) has been approved for use as a treatment for schizophrenia in adults. The efficacy of aripiprazole LAI as a maintenance treatment for schizophrenia has been demonstrated in randomized clinical trials. In the trials, aripiprazole LAI was more effective than placebo, and noninferior to oral aripiprazole, in delaying relapse and in reducing relapse rates in schizophrenia. Aripiprazole LAI was generally well tolerated, with a tolerability profile consistent with that of oral aripiprazole. Thus, aripiprazole LAI is a valuable new treatment option for adult patients with schizophrenia. It may be of particular use for patients stable on oral aripiprazole who would prefer, or are likely to benefit from, a long-acting formulation.

show abstract

“Meta-guidelines” for the management of patients with schizophrenia

Cited by 58 publications

References 9 publications

Adherence to Guidelines in Gynecologic Cancer Surgery

Adherence to Guidelines in Gynecologic Cancer Surgery

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics

Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia

Contact Info

Product

Resources

About